IMCR Graph | Immunocore Holdings plc

IMCR Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $115.93M; Cost of revenue $1.09M; Research and development $73.94M; Selling, general and administrative $43.89M.
2026-03-31: Revenue $106.68M; Cost of revenue $434.00K; Research and development $61.11M; Selling, general and administrative $37.85M.
2025-12-31: Revenue $104.48M*; Cost of revenue $2.70M*; Research and development $78.82M*; Selling, general and administrative $42.65M*.
2025-09-30: Revenue $103.69M; Cost of revenue $513.00K; Research and development $70.57M; Selling, general and administrative $39.78M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$115.93M	$1.09M	$73.94M	$43.89M	$294.00K	-$808.00K
2026-03-31	$106.68M	$434.00K	$61.11M	$37.85M	$301.00K	$12.97M
2025-12-31	$104.48M*	$2.70M*	$78.82M*	$42.65M*	$14.27M*	-$30.06M*
2025-09-30	$103.69M	$513.00K	$70.57M	$39.78M	$481.00K	-$177.00K
2025-06-30	$97.96M	$1.04M	$69.01M	$42.79M	$606.00K	-$10.30M
2025-03-31	$93.88M	$831.00K	$56.47M	$40.20M	$1.06M	$5.02M
2024-09-30	$80.25M	$448.00K	$52.77M	$35.53M	-$2.64M	$8.74M
2024-06-30	$75.40M	$1.71M	$51.07M	$38.64M	$1.49M	-$11.62M
2024-03-31	$70.50M	$246.00K	$57.46M	$39.29M	$357.00K	-$24.44M
2023-09-30	$64.85M	$276.00K	$43.25M	$35.47M	-$175.00K	$906.00K
2023-06-30	$59.76M	$346.00K	$38.16M	$35.01M	$191.00K	-$17.01M
2023-03-31	$54.66M	$216.00K	$36.57M	$32.57M	$293.00K	-$19.45M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$222.60M	$1.52M	$135.06M	$81.74M	$595.00K	$12.16M
2025-06-30	$191.84M	$1.87M	$125.48M	$82.99M	$1.67M	-$5.28M
2024-06-30	$145.90M	$1.95M	$108.53M	$77.92M	$1.84M	-$36.05M
2023-06-30	$114.42M	$562.00K	$74.73M	$67.58M	$484.00K	-$36.46M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-09-30	$295.54M	$2.38M	$196.05M	$122.77M	$2.15M	-$5.45M
2024-09-30	$226.15M	$2.40M	$161.30M	$113.46M	-$800.00K	-$27.32M
2023-09-30	$179.27M	$837.00K	$117.98M	$103.05M	$308.00K	-$35.56M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-12-31	$400.02M	$5.09M	$274.87M	$165.41M	$16.41M	-$35.51M
2024-12-31	$310.20M	$2.73M	$222.15M	$155.78M	-$1.85M	-$51.09M
2023-12-31	$249.43M	$1.04M	$163.54M	$144.50M	-$5.60M	-$55.29M
2022-12-31	$174.36M	$1.09M	$101.92M	$123.06M	$11.66M	-$52.54M
2021-12-31	(m)	$0.00	$100.25M	$110.82M	$150.00K	-$180.03M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Taysha Gene Therapies, Inc. (TSHA)	United States	$1.564B	-14.80
Hemab Therapeutics Holdings, Inc. (COAG)	United States	$1.672B
NOVAVAX INC (NVAX)	United States	$1.748B	-6.26
Inhibrx Biosciences, Inc. (INBX)	United States	$1.477B	-10.08
Maze Therapeutics, Inc. (MAZE)	United States	$1.457B	-12.40
Vir Biotechnology, Inc. (VIR)	United States	$1.814B	-6.85
Vericel Corp (VCEL)	United States	$2.011B	93.97
Replimune Group, Inc. (REPL)	United States	$1.186B	-3.13
RECURSION PHARMACEUTICALS, INC. (RXRX)	United States	$2.080B	-3.78
Kodiak Sciences Inc. (KOD)	United States	$2.090B	-10.12